PT  - JOURNAL ARTICLE
AU  - David J Price
AU  - Freya M Shearer
AU  - Michael T Meehan
AU  - Emma McBryde
AU  - Robert Moss
AU  - Nick Golding
AU  - Eamon J Conway
AU  - Peter Dawson
AU  - Deborah Cromer
AU  - James Wood
AU  - Sam Abbott
AU  - Jodie McVernon
AU  - James M McCaw
TI  - Early analysis of the Australian COVID-19 epidemic
AID  - 10.1101/2020.04.25.20080127
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.25.20080127
4099  - http://medrxiv.org/content/early/2020/04/30/2020.04.25.20080127.short
4100  - http://medrxiv.org/content/early/2020/04/30/2020.04.25.20080127.full
AB  - As of 18 April 2020, there had been 6,533 confirmed cases of COVID-19 in Australia [1]. Of these, 67 had died from the disease. The daily count of new confirmed cases was declining. This suggests that the collective actions of the Australian public and government authorities in response to COVID-19 were sufficiently early and assiduous to avert a public health crisis — for now. Analysing factors, such as the intensity and timing public health interventions, that contribute to individual country experiences of COVID-19 will assist in the next stage of response planning globally. Using data from the Australian national COVID-19 database, we describe how the epidemic and public health response unfolded in Australia up to 13 April 2020. We estimate that the effective reproduction number was likely below 1 (the threshold value for control) in each Australian state since mid-March and forecast that hospital ward and intensive care unit occupancy will remain below capacity thresholds over the next two weeks.Competing Interest StatementThis work was undertaken with direct funding support from the Australian Government Department of Health, Office of Health Protection and has assisted the Australian Government in its epidemic response activities.Funding StatementThis work was undertaken with direct funding support from the Australian Government Department of Health, Office of Health Protection.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets analysed and generated during this study are included in the supplementary materials. For estimates of the time-varying effective reproduction number (Figure 2), the complete line listed data within the Australian national COVID-19 database are not publicly available. However, we provide the cases per day by notification date and state (as shown in Figures 1 and S1) which, when supplemented with the estimated distribution of the delay from symptom onset to notification (samples from this distribution are provided as a data file), analyses of the time-varying effective reproduction number can be performed.